Novel immunotherapies in multiple myeloma - chances and challenges

被引：24

作者：

Rasche, Leo ^{[1
,2
]}

Wasch, Ralph ^{[3
]}

Munder, Markus ^{[4
,5
]}

Goldschmidt, Hartmut ^{[6
,7
]}

Raab, Marc S. ^{[6
,8
]}

机构：

[1] Univ Hosp Wurzburg, Dept Internal Med 2, Wurzburg, Germany

[2] Univ Hosp Wurzburg, Mildred Scheel Early Career Ctr, Wurzburg, Germany

[3] Univ Freiburg, Fac Med, Univ Med Ctr, Dept Internal Med 1, Freiburg, Germany

[4] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Med 3, Mainz, Germany

[5] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Res Ctr Immunotherapy, Mainz, Germany

[6] Univ Hosp Heidelberg, Dept Internal Med 5, Heidelberg, Germany

[7] Natl Ctr Tumor Dis NCT, Heidelberg, Germany

[8] German Canc Res Ctr, CCU Mol Hematol Oncol, Heidelberg, Germany

来源：

HAEMATOLOGICA | 2021年 / 106卷 / 10期

关键词：

T-CELL THERAPY; CAR-T; EXPRESSION; CD38;

D O I：

10.3324/haematol.2020.266858

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In this review article, we summarize the latest data on antibody-drug conjugates, bispecific T-cell-engaging antibodies, and chimeric antigen receptor T cells in the treatment of multiple myeloma. We discuss the pivotal questions to be addressed as these new immunotherapies become standard agents in the management of multiple myeloma. We also focus on the selection of patients for these therapies and speculate as to how best to individualize treatment approaches. We see these novel immunotherapies as representing a paradigm shift. However, despite the promising preliminary data, many open issues remain to be evaluated in future trials.

引用

页码：2555 / 2565

页数：11

共 61 条

[1] T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma [J].

Ali, Syed Abbas ;

Shi, Victoria ;

Maric, Irina ;

Wang, Michael ;

Stroncek, David F. ;

Rose, Jeremy J. ;

Brudno, Jennifer N. ;

Stetler-Stevenson, Maryalice ;

Feldman, Steven A. ;

Hansen, Brenna G. ;

Fellowes, Vicki S. ;

Hakim, Frances T. ;

Gress, Ronald E. ;

Kochenderfer, James N. .

BLOOD, 2016, 128 (13) :1688-1700

[2]

Berdeja JG, 2020, J CLIN ONCOL, V38

[3] T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma [J].

Brudno, Jennifer N. ;

Maric, Irina ;

Hartman, Steven D. ;

Rose, Jeremy J. ;

Wang, Michael ;

Lam, Norris ;

Stetler-Stevenson, Maryalice ;

Salem, Dalia ;

Yuan, Constance ;

Pavletic, Steven ;

Kanakry, Jennifer A. ;

Ali, Syed Abbas ;

Mikkilineni, Lekha ;

Feldman, Steven A. ;

Stroncek, David F. ;

Hansen, Brenna G. ;

Lawrence, Judith ;

Patel, Rashmika ;

Hakim, Frances ;

Gress, Ronald E. ;

Kochenderfer, James N. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (22) :2267-+

[4] TAK-169, a Novel Recombinant Immunotoxin Specific for CD38, Induces Powerful Preclinical Activity Against Patient-Derived Multiple Myeloma Cells [J].

Bruins, Wassilis S. C. ;

Zheng, Wenrou ;

Higgins, Jack P. ;

Willert, Erin K. ;

Newcomb, John ;

Dash, Ajeeta B. ;

Van de Donk, Niels W. C. J. ;

Zweegman, Sonja ;

Mutis, Tuna .

BLOOD, 2020, 136

[5] Targeted Therapy With Immunoconjugates for Multiple Myeloma [J].

Bruins, Wassilis S. C. ;

Zweegman, Sonja ;

Mutis, Tuna ;

van de Donk, Niels W. C. J. .

FRONTIERS IN IMMUNOLOGY, 2020, 11

[6] TNB383B.0001: A Multicenter, Phase 1, Open-Label, Dose-Escalation Andexpansion Study of TNB-383B, a Bispecific Antibodytargeting BCMA in Subjects with Relapsed or Refractorymultiple Myeloma [J].

Buelow, Ben ;

D'Souza, Anita ;

Rodriguez, Cesar ;

Vij, Ravi ;

Nath, Rajneesh ;

Snyder, Melinda ;

Pham, Duy ;

Patel, Ashwin ;

Iyer, Suhasini .

BLOOD, 2019, 134

[7] A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) [J].

Chari, Ajai ;

Berdeja, Jesus G. ;

Oriol, Albert ;

van de Donk, Niels W. C. J. ;

Rodriguez, Paula ;

Askari, Elham ;

Mateos, Maria-Victoria ;

Minnema, Monique C. ;

Verona, Raluca ;

Girgis, Suzette ;

Prior, Thomas ;

Hilder, Brandi W. ;

Russell, Jeffery ;

Goldberg, Jenna D. ;

Krishnan, Amrita .

BLOOD, 2020, 136

[8] Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma [J].

Cohen, Adam D. ;

Harrison, Simon J. ;

Krishnan, Amrita ;

Fonseca, Rafael ;

Forsberg, Peter A. ;

Spencer, Andrew ;

Berdeja, Jesus G. ;

Laubach, Jacob P. ;

Li, Mengsong ;

Choeurng, Voleak ;

Vaze, Anjali ;

Samineni, Divya ;

Sumiyoshi, Teiko ;

Cooper, James ;

Fine, Bernard M. ;

Trudel, Suzanne .

BLOOD, 2020, 136

[9] B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma [J].

Cohen, Adam D. ;

Garfall, Alfred L. ;

Stadtmauer, Edward A. ;

Melenhorst, J. Joseph ;

Lacey, Simon F. ;

Lancaster, Eric ;

Vogl, Dan T. ;

Weiss, Brendan M. ;

Dengel, Karen ;

Nelson, Annemarie ;

Plesa, Gabriela ;

Chen, Fang ;

Davis, Megan M. ;

Hwang, Wei-Ting ;

Young, Regina M. ;

Brogdon, Jennifer L. ;

Isaacs, Randi ;

Pruteanu-Malinici, Iulian ;

Siegel, Don L. ;

Levine, Bruce L. ;

June, Carl H. ;

Milone, Michael C. .

JOURNAL OF CLINICAL INVESTIGATION, 2019, 129 (06) :2210-2221

[10] First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial [J].

Costa, Luciano J. ;

Wong, Sandy W. ;

Bermudez, Arancha ;

de la Rubia, Javier ;

Mateos, Maria-Victoria ;

Ocio, Enrique M. ;

Rodriguez-Otero, Paula ;

San-Miguel, Jesus ;

Li, Shaoyi ;

Sarmiento, Rafael ;

Lardelli, Pilar ;

Gaudy, Allison ;

Boss, Isaac ;

Kelly, Lisa M. ;

Burgess, Michael R. ;

Hege, Kristen ;

Bensinger, William I. .

BLOOD, 2019, 134

← 1 2 3 4 5 6 7 →